

# Perinatally HIV-infected Adolescents and Young Adults: A Challenge of Care, Experience from a Regional Cohort

V. Reliquet<sup>1</sup>, V. Rabier<sup>2</sup>, P. Perre<sup>3</sup>, H. Hitoto<sup>4</sup>, L. Perez<sup>4</sup>, J.-M. Chennebault<sup>2</sup>, P. Fialaire<sup>2</sup>, C. Michau<sup>5</sup>, C. Allavena<sup>1</sup>, S. Sécher<sup>6</sup>, T. Jovelin<sup>6</sup>, F. Raffi<sup>1</sup>



PE20/9

1CHU Nantes, Infectious Dise ntes, France, <sup>2</sup>CHU Angers, Infectious Diseases, Angers, France, <sup>3</sup>CHD La Roche sur Yon, Internal Medicine, La Roche sur Yon, France

## **OBJECTIVE**


describe HIV and health status, psychosocial characteristics, education achievement and sexual behaviors of HIVpositive adolescents and young adults followed in a French administrative region "Pays de Loire".


# PATIENTS AND METHODS

prospective, multicentric study. Patients completed administered questionnaires. Physicians filled out standardized electronic medical

Inclusion criteria: 16 to 25 years old / HIV-1 infected perinatally or before 5 years / Oral informed consent.

## RESULTS





#### Immunologic and virologic status

		Median [IQR]	
CD4 (cells/mm <sup>3</sup> )	cell count	565	[334-752]
	nadir	198	[50-283]
CD4 cell count > 500 cells/mm <sup>3</sup>		15 (65%)	
HIV viral load < 50 c/mL		13 (56.5%)	

#### **Therapeutic status**


	Median [IQR]	
Age at first ARV therapy (years)	5	[1-8]
<b>Duration of ARV therapy</b> (years)	15	[11-20]
Current ARV therapy	n	(%)
2 NRTI + PI/r	9	(39%)
2 NRTI + NNRTI	6	(26%)
RAL + PI/r	5	(22%)
NRTI + NNRTI + RAL	1	(4%)
NRTI + NNRTI + RAL + PI/r	1	(4%)
Unstructured ART interruption	1	(4%)
Prevalence of resistance mutations (cumulative historical genotypes)		19
Protease	11	(58%)
Reverse Transcriptase	13	3 (68%)



Current marijuana use

	n (%)
Inconsistent use of condom	11(2M/9F) (69%)
Detectable HIV viral load	6 (55%)
Knowledge about post exposure prophylaxis	8 (50%)
Disclosed their HIV status to their partner	9 (56%)

2 (9%)



**ARV** adherence was considered as satisfactory 57% of clinicians versus 35% of patients.

## DISCUSSION

There was a high (26%) but not significant (p=0.11) rate of discordance for ARV adherence between clinicians' and patients' reports. 22% of youths (1 male, 4 female) had low BMI, 17% were overweight (4 women). Rate of substance use was lower for tobacco and marijuana compared to the general French students (26.8 and 21.4%, respectively). Compared with French teenagers, vaccination coverage for Hepatitis B and HPV was higher in our small cohort (43% and 29% vs 78% and 44%, respectively). Despite a high rate of grade repeating (65%), most of HIV-infected youths had diploma.

#### CONCLUSION

Despite a good health and a relative good immunological status, virological suppression rate was low and levels of resistance to PI and RTI high in these HIV-1 infected youths with over 15 years of ARV history. Safe sex practices should be promoted and adherence must be improved in this predominantly female population to preserve quality of life and life expectancy.

ACKNOWLEDGMENTS to all the patients that have participated to this study, the medical staff and the clinical research teams.

Véronique RELIQUET : veronique.reliquet@chu-nantes.fr